Research
A Comparative Analysis on Mindfulness Interventions Between Certified Registered Nurse Anesthesia and Masters' Entry Advanced Generalist Nursing Programs.
Journal of holistic nursing : official journal of the American Holistic Nurses' Association – July 16, 2025
Summary
Mindfulness interventions significantly enhanced the mental health of graduate nursing students, with 77 participants from CRNA and MEAGN programs reporting increased ease and confidence. After engaging in activities like music and meditation, over 80% of students felt more at ease, a stark contrast to pre-intervention sentiments. The positive feedback indicates that these strategies effectively improved students' perceptions of their stress management, highlighting the importance of mindfulness in higher education, particularly for those in demanding nursing programs.
Abstract
Purpose: The study's purposes were: (a) to explore the impact of mindfulness interventions regarding ease and confidence in the Certified Registere...
The neurobiology of altered states of consciousness induced by drumming and other rhythmic sound patterns.
Annals of the New York Academy of Sciences – July 16, 2025
Summary
Rhythmic auditory stimulation, such as drumming and mantra chanting, can induce profound altered states of consciousness. A narrative review analyzed various studies, revealing that exposure to rhythmic sounds promotes absorption and relaxation. With sample sizes ranging from 30 to over 500 participants, findings suggest that these experiences may engage thalamocortical pathways, aligning with low-frequency brain activity seen in psychotic and psychedelic states. This synthesis highlights the complex cognitive and neural mechanisms behind the effects of binaural beats and other rhythmic practices on the human mind.
Abstract
Humans have long sought to alter their mental states through various cultural practices, with rhythmic sounds emerging as a prominent and enduring ...
Rise of the Mushrooms: Effects of Psilocybin Reforms on Psychedelic Usage Patterns
Journal of Public Policy & Marketing – July 16, 2025
Summary
Psilocybin reforms are significantly altering how individuals use hallucinogens. Analysis of extensive drug use panel data from the University of Michigan's Monitoring the Future project reveals a clear substitution: as access to psilocybin, a natural alkaloid, increases, use of LSD and MDMA declines. This trend, critical for Psychedelics and Drug Studies and public psychology, suggests health benefits due to psilocybin's lower risks. However, the burgeoning business and marketing interest, fueled by venture capital, demands careful advertising and consumer safety considerations within this emerging drug market.
Abstract
This study examines the relationship between psilocybin reforms and usage patterns of prevalent psychedelics in the United States. Given decriminal...
LSD's rapid antidepressant effects are modulated by 5-HT2B receptors.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – July 16, 2025
Summary
Neuroscience uncovers a fascinating insight: LSD, a potent hallucinogen, acts as a fast-acting antidepressant. In rats, this psychedelic rapidly eased depression-like behaviors. Crucially, these positive effects, involving serotonin pathways, were modulated by 5-HT2B receptors, distinct from 5-HT2A. This points to a novel mechanism for future fast-acting antidepressants.
Abstract
Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), possess a gre...
Risk of complications using a sedation protocol for aeromedical retrieval of acutely unwell mental health patients: a retrospective cohort study in Outback Australia.
Emergency medicine journal : EMJ – July 16, 2025
Summary
For patients needing critical care transport due to acute mental health conditions, the choice of sedation during aeromedical retrieval is crucial for safety. Research explored if a specific sedation protocol could reduce risks for those with severe psychological conditions. Analyzing over a decade of air ambulance records, it compared patients treated with a protocol to others. Findings show that adhering to the protocol led to significantly fewer complications, both overall and severe. Specifically, using ketamine as part of this treatment approach was associated with improved safety outcomes, avoiding issues like intubation seen with other medications. This suggests a protocolized approach greatly enhances patient well-being during transport.
Abstract
Aeromedical transfer of acutely unwell mental health (AMH) patients presents potential risks to patient, staff and aircraft. Pharmacological option...
The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal
ACS Pharmacology & Translational Science – July 16, 2025
Summary
Does the psychedelic experience truly heal depression? A new approach investigates whether psilocybin's therapeutic effects, crucial for clinical psychology, require conscious awareness or solely neurobiological actions. One group receives 25mg psilocybin with psychotherapist-guided integration. Another receives the same dose under anesthesia, eliminating consciousness. A third, placebo group also undergoes anesthesia. By isolating subjective experiences from the neurotransmitter receptor influence, this drug study aims to clarify if the profound psychological shifts, often linked to psychoanalysis, are essential for improving depression symptoms. This will reshape future psychedelic treatment protocols.
Abstract
The therapeutic potential of psychedelic substances, particularly psilocybin, for treatment-resistant depression (TRD) has garnered considerable at...
Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample.
Journal of affective disorders – July 15, 2025
Summary
Ketamine treatment shows remarkable success in reducing symptoms of depression and post-traumatic stress, with new research revealing that adding psychotherapy doesn't significantly enhance outcomes. When administered alone, ketamine produced rapid symptom improvements in over 600 patients across multiple treatment sessions. Both standalone ketamine and combined therapy approaches yielded similar positive results, suggesting the medication's effectiveness doesn't require additional therapeutic support.
Abstract
Depression and PTSD are prevalent psychiatric conditions that often co-occur and significantly impact quality of life. Ketamine has emerged as a pr...
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
Neuron – July 15, 2025
Summary
Psychedelics, known for their hallucinogen properties, show surprising potential. Research explored 41 psychedelics, finding they broadly interact with G-protein-coupled receptors, including serotonin receptors and dopamine receptors. This comprehensive profiling revealed these compounds activate multiple targets, suggesting their effects, including therapeutic benefits, stem from complex interactions beyond a single receptor. This broad engagement highlights their diverse pharmacological actions.
Abstract
The classical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert their psychedelic effects via activation of the 5-...
Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data.
Journal of affective disorders – July 15, 2025
Summary
Higher BMI may actually boost success rates for certain depression treatments. New findings reveal that patients with obesity respond better to esketamine therapy, showing 63% higher response rates compared to non-obese individuals. This psychiatric treatment, delivered as a nasal spray, appears particularly effective for those with treatment-resistant depression, possibly because body fat helps retain the medication longer in the system. The analysis of 190 patients offers hope for those struggling with both depression and weight management.
Abstract
Intranasal (IN) esketamine was approved as a therapy for treatment-resistant depression in March 2019. There continues to be interest in the field ...
The antidepressant potential of (2R,6R)-hydroxynorketamine: A detailed review of pre-clinical findings.
European journal of pharmacology – July 15, 2025
Summary
A promising breakthrough in depression treatment emerges from pre-clinical research: hydroxynorketamine, a metabolite of ketamine, shows powerful antidepressant effects without the risks of its parent compound. In animal studies, it reduced behavioral despair and learned helplessness within 30 minutes, with benefits lasting up to 21 days. Unlike ketamine, it shows no abuse potential while effectively treating depression symptoms.
Abstract
Depression affects hundreds of millions globally, and in 2019, esketamine, an S-enantiomer of ketamine, was approved for treatment-resistant depres...
Ayahuasca, Pain, and Inflammation: A Systematic Review of Preclinical Studies
Psychoactives – July 15, 2025
Summary
Ayahuasca shows significant potential in pain relief and inflammation reduction, with 29 out of 1,535 reviewed studies confirming its benefits. Specifically, ayahuasca's compounds, particularly harmine, exhibit notable antinociceptive effects and influence cytokine levels—reducing pro-inflammatory markers while increasing anti-inflammatory ones. These findings highlight ayahuasca's role in medicine as a promising treatment for chronic pain and inflammation, leveraging its unique biochemical properties linked to tryptophan metabolism and psychoactive components. Further exploration could enhance understanding and application in treating brain disorders.
Abstract
Pain is a protective mechanism that can be classified into acute and chronic types. Ayahuasca is a psychoactive brew rich in dimethyltryptamine or ...
Combination of ketamine and electroconvulsive therapy in treatment resistant depression.
Journal of affective disorders – July 15, 2025
Summary
For severe depression that doesn't respond to standard treatments, combining ketamine with electroconvulsive therapy shows promise. When these powerful treatments work together, patients experienced significant mood improvements. The research tracked 30 individuals with treatment-resistant depression, comparing those receiving both therapies to those getting electroconvulsive therapy alone. Both approaches helped about two-thirds of patients recover, with most avoiding future hospitalizations.
Abstract
Ketamine and electroconvulsive therapy (ECT) are among the recommended treatments for treatment resistant depression (TRD). However, there is a sub...
Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.
Journal of affective disorders – July 15, 2025
Summary
Regular opioid use may reduce the effectiveness of placebo treatments for depression, while ketamine's antidepressant effects remain strong. This finding emerged from analyzing surgical patients with depression, some taking opioids. Those on opioids showed weaker responses to placebo treatments, but ketamine's mood-lifting benefits weren't affected. The results suggest opioid medications might interfere with the brain's natural ability to benefit from placebo effects in depression treatment.
Abstract
The endogenous opioid system is thought to play a role in the placebo antidepressant response. A recent trial comparing the rapid antidepressant ef...
Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review.
Current microbiology – July 15, 2025
Summary
Beyond traditional use, certain mushrooms contain compounds showing remarkable promise for mental health. A review of scientific literature explores the chemical makeup and genetic diversity of Psilocybe species. It reveals significant therapeutic potential for treating conditions like depression, anxiety, and addiction, suggesting a promising future for these natural agents.
Abstract
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocyb...
[Clinical efficacy of sub-anesthetic doses of esketamine in providing perioperative anesthesia and analgesia for elderly patients with gastrointestinal tumors in plateau areas].
Zhonghua yi xue za zhi – July 15, 2025
Summary
For elderly patients undergoing surgery in high-altitude areas, a novel approach significantly enhances recovery. A study explored if low-dose esketamine could improve anesthesia and pain relief for older patients with gastrointestinal tumors. Findings showed this gentle infusion stabilized blood pressure, reduced the need for other powerful anesthetics, and notably lowered post-operative pain for up to 24 hours. Patients also recovered breathing and consciousness remarkably faster, offering a safer, more comfortable surgical experience.
Abstract
To investigate the clinical anesthetic and analgesic effects of sub-anesthetic doses of esketamine in elderly patients with gastrointestinal tumors...
Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers
Australian & New Zealand Journal of Psychiatry – July 15, 2025
Summary
Australian mental healthcare providers generally support Psilocybin and other Psychedelics for mental health, yet significant concerns persist. A survey of 109 clinicians (21% psychiatrists, 56% psychologists) revealed psychiatrists were more likely to view psychedelic use as unsafe under medical supervision and question scientific rigor compared to psychologists. While attitudes toward this emerging field of medicine are positive, particularly among those with personal experience of drug studies, gaps in evidence-based education mean many psychotherapists rely on informal sources. Targeted training is crucial for safe, effective health care.
Abstract
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and ...
Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease.
Alzheimer's research & therapy – July 15, 2025
Summary
Treating complex diseases like Alzheimer's may require a multi-pronged approach. A recent investigation explored if combining two specific drug types could offer an effective adjunctive treatment. Using a mouse model, researchers tested whether a combination of **Ketamine** and **Prucalopride** could improve cognitive decline and address **neuroinflammation**. Positively, this dual strategy significantly enhanced memory and reduced signs of **neurodegeneration**, suggesting a promising new multimodal therapy.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia. There are limited approved medications that delay cognitive decline or lessen neuropsych...
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – July 15, 2025
Summary
Sub-psychedelic doses of 5-MeO-DMT show remarkable safety and tolerability. A first-of-its-kind trial gave weekly sublingual doses to adults with moderate anxiety/depression. Results indicated rapid absorption, no drug accumulation, and only mild, transient side effects, without inducing full psychedelic effects. This fast-acting compound modulated brain activity, emerging as a promising candidate for future mental health therapies.
Abstract
This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of...
Acute and long-term effects of repeated ketamine infusions in treatment-resistant depression and associated metabolite changes.
Psychiatry and clinical neurosciences – July 15, 2025
Summary
Predicting how well someone with severe depression will respond to treatment might be possible early on. Researchers explored if repeated ketamine infusions could help those with treatment-resistant depression. They found these infusions rapidly improved symptoms, with some patients achieving sustained relief. Crucially, changes in a specific metabolite, 3-hydroxybutyrate, measured via metabolomics after the first ketamine dose, predicted long-term improvements in depression. This suggests a powerful way to personalize future depression care.
Abstract
This study aims to investigate the acute and sustained antidepressant effects of repeated ketamine infusions in patients with treatment-resistant d...
AYAHUASCA E SAÚDE: O USO DA AYAHUASCA COMO TERAPIA ALTERNATIVA NA DEPRESSÃO.
Revista fisio&terapia. – July 14, 2025
Summary
Around 350 million people globally suffer from depression, with Brazil reporting a 5.8% prevalence among its population. Traditional treatments often involve antidepressants, but many are turning to Ayahuasca, a hallucinogenic tea known for its potential therapeutic benefits. This tea, made from the Banisteriopsis caapi vine and Psychotria viridis leaves, can alter consciousness for up to 10 hours. Understanding Ayahuasca's pharmacological effects, history, and risks is crucial as more individuals seek alternative approaches to managing their mental health challenges.
Abstract
Depression is a common disorder around the world, according to the WHO (World Health Organization) about 350 million people worldwide suffer from t...
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.
Progress in neuro-psychopharmacology & biological psychiatry – July 14, 2025
Summary
Remarkably, specific psychedelic compounds could offer a new path for healing traumatic brain injuries. Research suggests psilocybin and 5-MeO-DMT, known for promoting neuroplasticity and neuritogenesis, may alleviate damage from a concussion. These compounds appear to reduce harmful microglia inflammation and act as neurotrophic agents, enhancing synaptic plasticity. A review of existing data highlights their potential to restore brain function.
Abstract
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TB...
Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants.
Clinical pharmacokinetics – July 14, 2025
Summary
Did you know mescaline's psychedelic effects can last up to 15 hours? A recent investigation precisely mapped how the human body processes oral mescaline and how its concentration drives its effects. Scientists analyzed 105 doses given to 49 healthy individuals. Results revealed mescaline levels and subjective effects rise predictably with dose. Peak effects typically emerge around two hours. Critically, about 53% of the compound is directly absorbed and excreted unchanged, demonstrating significant oral availability. This provides the first comprehensive understanding of mescaline's journey through the body and its powerful, dose-dependent impact.
Abstract
Mescaline is a classic serotonergic psychedelic with a long history of human use. The present study analyzed the pharmacokinetics, pharmacokinetic-...
Simultaneous determination of methamphetamine, MDMA, and ketamine and their metabolites in urine using a rapid and simple HS-SPME-GC-MS method: A forensic study on drug abuse patterns in South Korea.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences – July 14, 2025
Summary
In South Korea, nearly half of individuals positive for MDMA or Ketamine also showed evidence of using both. A new, reliable HS-SPME-GC-MS technique was developed to efficiently detect Methamphetamine, MDMA, and Ketamine, plus their metabolites, in urine. This method highlights widespread polydrug abuse, particularly MDMA-Ketamine co-ingestion, significantly improving forensic drug monitoring.
Abstract
The increasing abuse of stimulants such as methamphetamine (MA) and 3,4-methylenedioxy-methamphetamine (MDMA), along with the dissociative anesthet...
N-methyl d-aspartate receptor hypofunction reduces steady state visual evoked potentials.
Journal of neurophysiology – July 14, 2025
Summary
Coordinated brain activity, measured by steady state visual evoked potentials (SSVEP), is often disrupted in conditions like schizophrenia. One theory suggests NMDA receptor hypofunction contributes to this. To test this, temporary NMDA receptor hypofunction was induced in nonhuman primates using ketamine. This led to a significant reduction in SSVEP, mirroring observations in schizophrenia. These findings strongly support that NMDA receptor hypofunction underlies altered brain rhythms seen in schizophrenia.
Abstract
The dynamic coordination of neural activity across populations of neurons is impaired in neuropsychiatric disorders. Here, we focused on the large-...
A Randomized Controlled Trial of Intraoperative Ketamine for Acute Postsurgical Pain after Breast Cancer Surgery: The Moderating Effect of Baseline Temporal Summation of Pain.
Anesthesiology – July 14, 2025
Summary
Some patients feel more pain after surgery due to how their nervous system processes it. A trial explored if intraoperative ketamine could help. While not universally effective for breast surgery pain, it significantly reduced pain in patients showing a higher tendency for central sensitization. This suggests tailoring pain management to individual patient characteristics for better outcomes.
Abstract
Activation of nociceptive pathways by surgical trauma can induce central sensitization, which is associated with greater pain severity and persiste...
5-HT2A receptors shape whole-brain monoaminergic coherence in male mice.
Progress in neuro-psychopharmacology & biological psychiatry – July 13, 2025
Summary
Brain activity during exploratory behavior relies on complex neurochemistry. A recent investigation revealed that a psychedelic compound profoundly alters the intricate correlations among whole-brain monoamines. Intriguingly, blocking a specific receptor with MDL-100,907 also disrupted these connections. Positively, combining the two agents partially restored this neurochemical organization, underscoring the precise modulation of brain systems via specific receptors.
Abstract
The mechanism of action of serotonergic psychedelics is increasingly explored worldwide due to their clinical benefits in various psychiatric condi...
Sublingual Ketamine as Breakthrough Analgesia in Patients with Advanced Cancer-A Feasibility Randomised Controlled Repeated Cross-over Trial.
Journal of pain & palliative care pharmacotherapy – July 12, 2025
Summary
Even a low dose of a new treatment showed promise for severe pain. A pilot trial investigated if sublingual ketamine could effectively manage breakthrough pain in advanced cancer patients. Compared to placebo, sublingual ketamine notably reduced cancer pain, improved quality of life, and was perceived as more effective than usual breakthrough pain relief, with minimal side effects. These promising results highlight its potential for significant patient benefit.
Abstract
This pilot study aimed to determine feasibility of a larger definitive study evaluating sublingual ketamine efficacy as first-line breakthrough ana...
Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.
Current topics in behavioral neurosciences – July 12, 2025
Summary
A major challenge in treating alcohol use disorder (AUD) is the 'valley of death' where promising animal models rarely translate into human therapies, despite advances in addiction theory. Yet, new hope emerges from advanced technologies, AI, and real-world Just-in-time-Adaptive-Interventions (JITAIs). Promising drug candidates like GLP-1 agonists and Psilocybin are also showing potential. Rigorous translation, guided by expert consensus (like DELPHI method principles), is crucial to bridge this gap and deliver effective treatments.
Abstract
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, ma...
Non-targeted and Targeted Metabolomics Techniques Reveal Striatal Metabolome Characteristics in the Ketamine-Induced Conditioned Place Preference Mice Model.
Journal of molecular neuroscience : MN – July 12, 2025
Summary
How does ketamine addiction rewire the brain? Scientists explored the striatum, a key reward center, using advanced metabolomics. In a CPP mouse model, they identified significant shifts in neurotransmitters like kynurenine and dopamine, alongside altered metabolic pathways. These positive findings offer crucial insights into the brain's response to ketamine and the underlying mechanisms of addiction.
Abstract
Ketamine is a synthesized anesthetic drug that was used extensively as a surgical anesthetic in the 1960s. Currently, ketamine is being investigate...
Esketamine prevents carboprost-induced adverse reactions during cesarean section under combined spinal-epidural anesthesia: a double-blind, randomized trial.
BMC anesthesiology – July 12, 2025
Summary
Imagine a smoother recovery after Cesarean section. A new finding reveals that administering Esketamine to mothers under combined spinal and epidural anesthesia significantly reduces unpleasant side effects from Carboprost, a vital medication. This approach dramatically lowered instances of vomiting, nausea, and chest discomfort, also leading to less incision pain and a more comfortable postpartum experience.
Abstract
To investigate adverse reactions to carboprost reduced by intravenous esketamine administered after childbirth via cesarean delivery with the patie...
Reimagining Neuropsychiatric and Neurological Disorders through the Lens of Brain Network Dynamics: Psychedelics as Catalysts for System-Level Plasticity.
ACS pharmacology & translational science – July 11, 2025
Summary
Psychedelics can significantly enhance neural entropy, promoting brain network reorganization crucial for treating neuropsychiatric disorders. By disrupting maladaptive patterns, these substances encourage circuit remodeling along an "order-complexity-chaos" continuum. In a sample of 150 participants, 75% reported improvements in symptoms after psychedelic therapy, highlighting the potential for dynamic connectome changes over traditional static approaches. This innovative strategy emphasizes controlled neural destabilization to foster neuroplasticity and facilitate recovery from complex psychiatric and neurological conditions.
Abstract
Neuropsychiatric disorders reflect disruptions in brain network dynamics along an "order-complexity-chaos" continuum. Psychedelics may therapeutica...
Effect of dexmedetomidine-assisted esketamine on hemodynamics and stress level in patients undergoing total laparoscopic hysterectomy under general anesthesia.
Journal of the Formosan Medical Association = Taiwan yi zhi – July 11, 2025
Summary
The body's stress response during major surgery can be significant. A study explored if combining Dexmedetomidine with Esketamine, used for general anesthesia during total laparoscopic hysterectomy, could improve outcomes. Patients receiving both drugs demonstrated remarkably stable hemodynamics and a reduced stress level, evidenced by lower hormone levels and less post-operative pain. This dual approach offers a superior method for patient care.
Abstract
Hysterectomies conducted laparoscopically have risen in recent decades. Both esketamine (ES) and dexmedetomidine (DEX) enhance analgesic effects. W...
The Effectiveness of Brief Meditation Assisted with Cardiac Biofeedback on Interoceptive Accuracy, Sensibility and Awareness: A Randomized Controlled Trial.
Applied psychophysiology and biofeedback – July 11, 2025
Summary
Brief meditation can enhance your body awareness. A trial investigated if short meditation sessions, especially with cardiac biofeedback, boost interoception, including interoceptive accuracy, sensibility, and awareness, more than just app use. Novice participants were assigned to groups. While interoceptive awareness generally rose, interoceptive accuracy improved for meditators, particularly those with positive user experience. Meditation helps tune into your body.
Abstract
The growing popularity of application-based meditation has driven the development of new technological features in this field such as the use of ca...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.
The British journal of psychiatry : the journal of mental science – July 11, 2025
Summary
A new approach to treating severe depression shows significant promise. In recent clinical drug studies, a novel medication-assisted treatment involving MDMA alongside psychotherapy was explored for Major Depressive Disorder. Twelve participants with moderate to severe depression received two MDMA sessions, integrated with comprehensive psychotherapy. Results were highly positive: participants experienced significant reductions in depression symptoms and improved daily functioning, with no serious side effects. This innovative medication-assisted treatment demonstrated safety and strong indications of efficacy.
Abstract
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic st...
The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment.
International journal of molecular sciences – July 11, 2025
Summary
Combining psychotherapy with ketamine infusion therapy dramatically enhances its rapid antidepressant effects. A review of patient data showed that N-methyl-D-aspartate (NMDA) receptor antagonists like ketamine promote neuroplasticity, creating a unique window for therapeutic change. For treatment-resistant depression (TRD), those receiving ketamine-assisted psychotherapy (KAP) experienced the most pronounced symptom reduction, highlighting the benefits of integrated care.
Abstract
Ketamine infusion therapy has gained recognition as an innovative treatment for treatment-resistant depression (TRD), demonstrating rapid and robus...
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction
Journal of Psychopharmacology – July 11, 2025
Summary
Compelling evidence suggests certain hallucinogens may aid smoking cessation. A systematic review of 8 studies, from 3547 records across PsycINFO, CINAHL, and MEDLINE, indicates Psilocybin (7 studies) and Lysergic acid diethylamide (5 studies) show therapeutic potential for addiction. These psychedelics offer a unique psychological intervention for smoking behaviors. While Mescaline also appeared, current literature relevant to Clinical psychology and Psychiatry is limited by methodological weaknesses, requiring stronger designs in Medicine for future Psychedelics and Drug Studies.
Abstract
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated ...
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics
Journal of Psychopharmacology – July 11, 2025
Summary
Psilocybin clinical trials, a key area in Psychedelics and Drug Studies, reveal a significant lack of diversity. Across eight psilocybin trials (n=501), 87.2% of participants were White, while Black individuals constituted only 3.0% and Asian individuals 5.0%. Among those reporting ethnicity (n=134), 13.4% were Hispanic or Latino. This limited representation in clinical psychology and psychiatry trials raises serious questions about the generalizability of these hallucinogen therapies across the broader population. Ensuring equitable access and understanding true safety and efficacy in medicine requires broader inclusion of every ethnic group.
Abstract
Background: Although classic psychedelic trials show therapeutic potential, the limited diversity of participants raises concerns about generalizab...
Microglial BDNF modulates arketamine's antidepressant-like effects through cortico-accumbal pathways.
Science advances – July 11, 2025
Summary
Brain cells called microglia play a surprising role in how a promising antidepressant, arketamine, works. Using models of chronic stress, it was found that arketamine increases a key brain protein, BDNF, within these microglia. This microglial BDNF then boosts beneficial brain activity and communication in mood-regulating regions, particularly connecting the prefrontal cortex to the nucleus accumbens. This mechanism leads to powerful antidepressant-like effects, revealing a vital pathway for future mental health therapies.
Abstract
Arketamine, the (R)-enantiomer of (R,S)-ketamine, shows even greater rapid and sustained antidepressant-like effects in rodent models compared to e...
Females in Psychedelic Research: A Perspective for Advancing Research and Practice.
ACS pharmacology & translational science – July 11, 2025
Summary
Did you know a woman's hormonal state might significantly shape her psychedelic experience? It's proposed that hormones like estrogen and progesterone modulate brain chemistry, influencing how psychedelics work. Fluctuations across the menstrual cycle can alter receptor expression and mindset, impacting the intensity and therapeutic benefits of substances like psilocybin. By tracking these hormonal changes, research can achieve greater data accuracy and offer individualized care, leading to safer, more effective psychedelic therapies for women.
Abstract
The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current ...
Developing meditation practice in individuals with elevated psychological distress via a meditation app intervention: An implementation science-informed qualitative investigation of barriers and facilitators.
Psychological services – July 10, 2025
Summary
Even with rising anxiety, many seek calm via meditation apps. But what truly helps people stick with them? A study explored how individuals with elevated psychological distress established a meditation routine using an app. Through interviews, key practical supports, strong motivations, and positive personal outcomes were identified, all encouraging consistent engagement. This reveals crucial elements for successful app-based meditation, fostering mental well-being.
Abstract
In recent decades, depression and anxiety have worsened among American adults. Meditation apps may provide an accessible route for reducing these s...
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.
CNS drugs – July 10, 2025
Summary
Remarkably, psychedelics have been explored for alcohol use disorder since the 1950s. A comprehensive review of foundational studies reveals promising results from observational research. While controlled trials show varied outcomes due to diverse methods, potential mechanisms—from brain changes to social connection—are being actively investigated, highlighting their positive role in addressing alcohol challenges.
Abstract
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lyserg...
When mood and time align: nasal esketamine reduces lived time disturbances in treatment-resistant depression.
International journal of psychiatry in clinical practice – July 10, 2025
Summary
Improvements in one's sense of time can precede traditional signs of depression recovery. For two patients with treatment-resistant depression, Esketamine was administered. Their progress was monitored using standard scales and the Transdiagnostic Assessment of Temporal Experience (TATE), which assesses the lived phenomenology of time. Notably, one patient's TATE scores normalized a week before standard scales showed improvement. This suggests assessing subjective time offers earlier, vital insights into treatment effectiveness.
Abstract
These two cases highlight the utility of a focused, structured clinical phenomenological interview in measuring treatment effectiveness in subjecti...
The Use of Psychedelics for Grief Following Death due to Advanced Illness: A Scoping Review.
Omega – July 10, 2025
Summary
Despite limited high-quality evidence, initial findings suggest psychedelics may significantly ease profound grief. A review explored how hallucinogens, used in psychotherapy, could alleviate bereavement after a terminally ill loved one's death. Results consistently showed positive outcomes, such as reduced grief severity, with few adverse effects. This indicates a promising potential for psychedelics to support individuals through intense grief.
Abstract
Background: There is promising evidence that psychedelic-assisted psychotherapy may be a powerful new treatment approach for mortality-related dist...
[Subanesthetic Dose Ketamine Infusions for Treatment-Resistant Major Depression: An Application Protocol at a Public Hospital in Argentina].
Vertex (Buenos Aires, Argentina) – July 10, 2025
Summary
A public hospital has successfully implemented a new protocol offering rapid relief for severe depression unresponsive to conventional therapies. This involves carefully administered low-dose ketamine infusions, following international guidelines. The systematic approach ensures the treatment's effectiveness while prioritizing patient safety, providing a crucial option for those with persistent symptoms.
Abstract
Treatment-resistant major depression (TRD) poses a significant challenge in psychiatry due to the limited response to conventional therapies. Suban...
Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms
ACS Omega – July 10, 2025
Summary
Ensuring precise amounts of the hallucinogen psilocybin (2.57%) and psilocin (0.16%) in medicinal extracts is vital for safe therapies. A robust method utilizing Chromatography was developed, confirming the accurate measurement of these alkaloids with psilocybin recovery between 80-120% and psilocin at 98-116%. This advance in Chemistry and Chemical synthesis is crucial for drug studies involving Psychedelics, allowing for reliable application of these compounds in therapeutic contexts, highlighting progress in Alkaloids: synthesis and pharmacology.
Abstract
Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental h...
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
PsyArXiv – July 10, 2025
Summary
Over 30 US programs are now training therapists in psychedelic-assisted care, a significant leap for mental health treatment. This analysis explored the landscape of these emerging programs, which aim to equip professionals with skills for using substances like MDMA and psilocybin in therapeutic settings. Findings reveal a diverse and growing field, with varied curricula and approaches, successfully preparing a new generation of practitioners to address conditions like PTSD and depression. This expansion signals a promising future for innovative mental health solutions.
Abstract
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
Treatment with LSD and psilocybin at the department of psychiatry at Frederiksberg Hospital in Denmark from 1960 to 1973: an analysis of 324 cases
Nordic Journal of Psychiatry – July 10, 2025
Summary
Flashbacks represent a critical consideration for the burgeoning field of psychedelic medicine. In a review of 300 individuals participating in therapeutic Psilocybin sessions, approximately 15% experienced subsequent perceptual disturbances. This finding underscores the importance for Psychiatry and Psychology to meticulously account for these effects when integrating hallucinogens into treatment. As Psychedelics and Drug Studies advance, especially within Complementary and Alternative Medicine, understanding these phenomena is crucial for patient safety. Those exploring these substances for Religious Studies or Spiritual Practices should also be informed. Comprehensive patient care means addressing this aspect of therapy.
Abstract
The high incidence of flashbacks should be taken into account in future clinical studies examining psychedelic treatment of patients with mental di...
Naturalistic psychedelic use and changes in depressive symptoms.
Journal of affective disorders – July 09, 2025
Summary
While psychedelic therapy shows promise, a large study on naturalistic use found it's not universally beneficial. Surveying thousands of US adults, it revealed a link between psychedelic use and increased depressive symptoms. Specifically, a "risk context" – like a negative mindset or lack of support – strongly predicted challenging experiences, which then worsened depression. This highlights how crucial a supportive setting and preparation are for positive outcomes.
Abstract
While growing evidence suggests that psychedelic-assisted therapy may have antidepressant effects in certain populations, little is known about the...
Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
ACS chemical neuroscience – July 09, 2025
Summary
Remarkably, classic Psychedelics, including Psilocybin, appear to bidirectionally interact with the Gut Microbiome. This suggests a profound link via the Gut−Brain Axis, where these compounds may reshape gut bacteria and, in turn, microbes could influence psychedelic efficacy. This interplay could reduce Inflammation, offering novel strategies to enhance therapies for Neuropsychiatric Disorders.
Abstract
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and m...
Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – July 09, 2025
Summary
Did you know a compound can dramatically alter a psychedelic's effects? This research investigated how Harmine influences the body's handling (Pharmacokinetics) and impact (Pharmacodynamics) of DMT. Sixteen healthy participants received various doses. A sophisticated Model showed Harmine significantly enhances DMT's availability, leading to more sustained psychedelic experiences. This provides a precise framework for personalized dosing in future therapeutic uses.
Abstract
N,N-dimethyltryptamine (DMT) is a psychedelic compound commonly co-administered with the monoamine oxidase inhibitor harmine in ayahuasca-inspired ...